← All trials
NCT05266807
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 16, 2022
- Primary completion
- Jan 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Mar 4, 2022
- Last posted
- Aug 17, 2022
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LausanneLead sponsor
- University of LausanneOverall official - principal investigator
- University of LausanneSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.